|
All admitted patients N = 92 |
Patients with VTE during hospitalization N = 29 |
Patients without VTE during hospitalization N = 58 |
|
|---|---|---|---|
| Age (years) | 67 ± 13 | 67 ± 11 | 68 ± 12 |
| Male (%) | 67 (73) | 22 (76) | 41 (71) |
| BMI (kg/m2) | 29 ± 5 | 29 ± 4 | 30 ± 6 |
| Active cancer (N) | 4 | 3 | 1 |
| VTE on admission | 5 | 0 | ‐ |
| Heparins: | |||
|
Dalteparin: half‐therapeutic (%) Dalteparin/UH: therapeutic Dalteparin/UH: prophylactic Fondaparinux None |
68 (73.9) 14 (15.2) 8 (8.7) 1 (1.1) 1 (1.1) |
21 (72.4) 3 (11.4) 5 (17.2) ‐ ‐ |
47 (81.0) 7 (12.1) 3 (5.2) ‐ 1 (1.7) |
| Major bleeding | 9 (9.8) | 5 (17.2) | 4 (6.9) |
| In‐hospital mortality | 27 (29.3) | 10 (34.4) | 16 (27.5) |
| ICU length of stay (weeks) | 4 ± 2 | 5 ± 3 | 3 ± 2 |
BMI – body mass index, UH‐unfractionated heparin